Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All zinc studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchZincZinc (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality 30% Improvement Relative Risk Death/ICU 38% ICU admission 54% Oxygen therapy, day 30 42% Oxygen therapy, day 15 23% Recovery, day 30 29% Recovery, day 15 14% Hospitalization, outpatients 69% Hospitalization time, inpat.. 33% Recovery time, outpatients 25% Zinc  VIZIR  EARLY TREATMENT  DB RCT Is early treatment with zinc beneficial for COVID-19? Double-blind RCT 470 patients in Tunisia (February - May 2022) Lower death/ICU (p=0.04) and ICU admission (p=0.01) c19early.org Abdallah et al., Clinical Infectious D.., Nov 2022 Favors zinc Favors control

Twice daily oral zinc in the treatment of patients with Coronavirus Disease-19: A randomized double-blind controlled trial

Abdallah et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac807, VIZIR, NCT05212480
Nov 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
Zinc for COVID-19
2nd treatment shown to reduce risk in July 2020
 
*, now known with p = 0.0000013 from 44 studies, recognized in 11 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,100+ studies for 60+ treatments. c19early.org
RCT 470 patients with symptoms ≤7 days, showing significantly lower ICU admission and combined mortality/ICU admission with zinc treatment. Greater benefit was seen for patients treated within 3 days. 25mg elemental zinc bid for 15 days.
See also academic.oup.com and the author's reply academic.oup.com (B).
risk of death, 29.9% lower, RR 0.70, p = 0.27, treatment 15 of 231 (6.5%), control 22 of 239 (9.2%), NNT 37, odds ratio converted to relative risk, day 30.
risk of death/ICU, 37.6% lower, RR 0.62, p = 0.04, treatment 24 of 231 (10.4%), control 40 of 239 (16.7%), NNT 16, odds ratio converted to relative risk, day 30.
risk of ICU admission, 54.0% lower, RR 0.46, p = 0.01, treatment 12 of 231 (5.2%), control 27 of 239 (11.3%), NNT 16, odds ratio converted to relative risk, day 30.
risk of oxygen therapy, 41.7% lower, RR 0.58, p = 0.009, treatment 31 of 231 (13.4%), control 55 of 239 (23.0%), NNT 10, grade III, day 30, Figure 3.
risk of oxygen therapy, 22.9% lower, RR 0.77, p = 0.003, treatment 108 of 231 (46.8%), control 145 of 239 (60.7%), NNT 7.2, grade III, day 15, Figure 3.
risk of no recovery, 29.3% lower, RR 0.71, p = 0.002, treatment 82 of 231 (35.5%), control 120 of 239 (50.2%), NNT 6.8, grade II/III, day 30.
risk of no recovery, 13.8% lower, RR 0.86, p < 0.001, treatment 180 of 231 (77.9%), control 216 of 239 (90.4%), NNT 8.0, grade II/III, day 15.
risk of hospitalization, 69.1% lower, RR 0.31, p = 0.30, treatment 1 of 85 (1.2%), control 4 of 100 (4.0%), NNT 35, odds ratio converted to relative risk, outpatients.
hospitalization time, 33.0% lower, relative time 0.67, p < 0.001, treatment mean 7.1 (±3.4) n=146, control mean 10.6 (±2.8) n=134, inpatients.
recovery time, 25.0% lower, relative time 0.75, p < 0.001, treatment mean 9.6 (±4.1) n=85, control mean 12.8 (±6.7) n=100, outpatients.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Abdallah et al., 4 Nov 2022, Double Blind Randomized Controlled Trial, placebo-controlled, Tunisia, peer-reviewed, mean age 54.2, 24 authors, study period 15 February, 2022 - 4 May, 2022, average treatment delay 4.6 days, trial NCT05212480 (history) (VIZIR). Contact: semir.nouira@rns.tn, belhajalikhaoula@yahoo.fr.
This PaperZincAll
Abstract: Clinical Infectious Diseases RESEARCH ARTICLE SC RI PT Twice daily oral zinc in the treatment of patients with Coronavirus Disease-19 A randomized double-blind controlled trial A N U Saoussen Ben Abdallah1, MD Yosra Mhalla13, MD Imen Trabelsi3, PhD Adel Sekma2,3, MD Rim Youssef3,4, MD Khaoula Bel Haj Ali2,3, MD Houda Ben Soltane3,5, MD HajerYacoubi3,4, MD Mohamed Amine Msolli2,3, MD Nejla Stambouli6, PhD Kaouthar Beltaief2,3, MD Mohamed Habib Grissa2,3, MD Meriem Khrouf3,5, MD Zied Mezgar3,5, MD Chawki Loussaief7, MD Wahid Bouida2,3, MD Rabie Razgallah8, MD Karima Hezbri9, PhD Asma Belguith10, MD Naouel Belkacem11, MD Zohra Dridi12, MD Hamdi Boubaker2,3, MD Riadh Boukef3,4, MD Semir Nouira2,3, MD 1 Medical intensive care unit, Fattouma Bourguiba University Hospital, 5000 Monastir, Tunisia; Emergency Department, Fattouma Bourguiba University Hospital, 5000 Monastir, Tunisia; 3 Research Laboratory LR12SP18 University of Monastir, 5019 Tunisia; 4Emergency Department, Sahloul University Hospital, 4011 Sousse, Tunisia; 5Emergency Department, Farhat Hached University Hospital, 4011 Sousse, Tunisia; 6UR17DN03 - Research Unit, Military Defense, Military Hospital of Tunis, Tunisia; 7Department of Infectious Disease Fattouma Bourguiba University Hospital, 5000 Monastir, Tunisia; 8DACIMA Consulting 1053 Tunis, Tunisia; 9 Medical affairs manager, Opalia Recordati, Tunis, Tunisia; 10Department of Preventive Medicine, TE D M 2 EP —————————————————————————————————————————— CC Corresponding author: Pr. Semir Nouira, Emergency Department and Laboratory Research (LR12SP18), Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia; +216 73 106 046. E-mail : semir.nouira@rns.tn. A Alternate corresponding author: Dr. Khaoula Bel Haj Ali, Emergency Department and Laboratory Research (LR12SP18), Fattouma Bourguiba University Hospital, 5000, Monastir, Tunisia. +216 29777277. E-mail : belhajalikhaoula@yahoo.fr. © The Author(s) 2022. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_ publication_model) DOI: 10.1093/cid/ciac807 1 Fattouma Bourguiba University Hospital, 5000 Monastir, Tunisia; 11District hospital Teboulba, Tunisia; 12Department of cardiology, Fattouma Bourguiba University Hospital, 5000 Monastir, Tunisia; 13Laboratory of microbiology, Fattouma Bourguiba University Hospital, 5000 Monastir, Tunisia; SC RI PT Background: Zinc supplementation has been considered one of the potential therapies for coronavirus disease-19 (COVID-19). We aimed to examine zinc efficacy in adult patients with COVID-19 infection. U Methods: We conducted a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Patients tested positive for COVID-19 without end organ failure were randomized to oral zinc (n=231) or matching placebo (n=239) for 15 days. The primary combined outcome was death due to COVID-19 or ICU admission within 30 days after randomization. Secondary outcomes included length of hospital stay for inpatients and duration of COVID-19 symptoms with COVID19 related hospitalization for outpatients. TE D M A N Findings: One hundred ninety patients (40.4%) were ambulatory and 280..
{ 'DOI': '10.1093/cid/ciac807', 'ISSN': ['1058-4838', '1537-6591'], 'URL': 'http://dx.doi.org/10.1093/cid/ciac807', 'abstract': '<jats:title>Abstract</jats:title>\n' ' <jats:sec>\n' ' <jats:title>BACKGROUND</jats:title>\n' ' <jats:p>Zinc supplementation has been considered one of the potential ' 'therapies for coronavirus disease-19 (COVID-19). We aimed to examine zinc efficacy in adult ' 'patients with COVID-19 infection.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>METHODS</jats:title>\n' ' <jats:p>We conducted a prospective, randomized, double-blind, ' 'placebo-controlled, multicenter trial. Patients tested positive for COVID-19 without end ' 'organ failure were randomized to oral zinc (n\u2009=\u2009231) or matching placebo (n\u2009' '=\u2009239) for 15 days. The primary combined outcome was death due to COVID-19 or ICU ' 'admission within 30 days after randomization. Secondary outcomes included length of hospital ' 'stay for inpatients and duration of COVID-19 symptoms with COVID-19 related hospitalization ' 'for outpatients.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>FINDINGS</jats:title>\n' ' <jats:p>One hundred ninety patients (40.4%) were ambulatory and 280 ' 'patients (59.6%) were hospitalized. Mortality at 30-day was 6.5% in Zinc group and 9.2% in ' 'Placebo group [odds ratio (OR) 0.70 (0.37-1.32)]; ICU admission rate was respectively 5.2% ' 'and 11.3% [OR 0.46 (0.23-0.88)]. Combined outcome was lower in zinc group compared to placebo ' 'group [OR 0.62 (0.38-0.99)]. Consistent results were observed in prespecified subgroups of ' 'patients with age\u2009&amp;lt;\u200965 years, those with comorbidity, and those who needed ' 'oxygen therapy at baseline. Length of hospital stay was shorter in zinc group compared to ' 'placebo group [difference 3.5 days, 95% CI (2.76-4.23)] in inpatients group; duration of ' 'COVID-19 symptoms decreased with zinc treatment compared to placebo in outpatients ' '[difference 1.9 days, 95% CI (0.62-2.6)]. No severe adverse events were observed during the ' 'study.</jats:p>\n' ' </jats:sec>\n' ' <jats:sec>\n' ' <jats:title>INTERPRETATION</jats:title>\n' ' <jats:p>Our results showed that in COVID-19 patients, oral zinc can ' 'decrease 30-day death and ICU admission rate and can shorten symptoms duration.</jats:p>\n' ' </jats:sec>', 'author': [ { 'affiliation': [ { 'name': 'Medical intensive care unit, Fattouma Bourguiba University ' 'Hospital , 5000 Monastir , Tunisia'}], 'family': 'Abdallah', 'given': 'Saoussen Ben', 'sequence': 'first'}, { 'affiliation': [ { 'name': 'Laboratory of microbiology, Fattouma Bourguiba University ' 'Hospital , 5000 Monastir , Tunisia'}], 'family': 'Mhalla', 'given': 'Yosra', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}], 'family': 'Trabelsi', 'given': 'Imen', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Emergency Department, Fattouma Bourguiba University Hospital , ' '5000 Monastir , Tunisia'}, { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}], 'family': 'Sekma', 'given': 'Adel', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}, { 'name': 'Emergency Department, Sahloul University Hospital , 4011 Sousse ' ', Tunisia'}], 'family': 'Youssef', 'given': 'Rim', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Emergency Department, Fattouma Bourguiba University Hospital , ' '5000 Monastir , Tunisia'}, { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}], 'family': 'Ali', 'given': 'Khaoula Bel Haj', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}, { 'name': 'Emergency Department, Farhat Hached University Hospital , 4011 ' 'Sousse , Tunisia'}], 'family': 'Soltane', 'given': 'Houda Ben', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}, { 'name': 'Emergency Department, Sahloul University Hospital , 4011 Sousse ' ', Tunisia'}], 'family': 'Yacoubi', 'given': 'Hajer', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Emergency Department, Fattouma Bourguiba University Hospital , ' '5000 Monastir , Tunisia'}, { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}], 'family': 'Msolli', 'given': 'Mohamed Amine', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'UR17DN03 - Research Unit, Military Defense, Military Hospital of ' 'Tunis , Tunisia'}], 'family': 'Stambouli', 'given': 'Nejla', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Emergency Department, Fattouma Bourguiba University Hospital , ' '5000 Monastir , Tunisia'}, { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}], 'family': 'Beltaief', 'given': 'Kaouthar', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Emergency Department, Fattouma Bourguiba University Hospital , ' '5000 Monastir , Tunisia'}, { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}], 'family': 'Grissa', 'given': 'Mohamed Habib', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}, { 'name': 'Emergency Department, Farhat Hached University Hospital , 4011 ' 'Sousse , Tunisia'}], 'family': 'Khrouf', 'given': 'Meriem', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}, { 'name': 'Emergency Department, Farhat Hached University Hospital , 4011 ' 'Sousse , Tunisia'}], 'family': 'Mezgar', 'given': 'Zied', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Infectious Disease Fattouma Bourguiba University ' 'Hospital , 5000 Monastir , Tunisia'}], 'family': 'Loussaief', 'given': 'Chawki', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Emergency Department, Fattouma Bourguiba University Hospital , ' '5000 Monastir , Tunisia'}, { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}], 'family': 'Bouida', 'given': 'Wahid', 'sequence': 'additional'}, { 'affiliation': [{'name': 'DACIMA \xa0 Consulting 1053 Tunis , Tunisia'}], 'family': 'Razgallah', 'given': 'Rabie', 'sequence': 'additional'}, { 'affiliation': [{'name': 'Medical affairs manager, Opalia Recordati , Tunis , Tunisia'}], 'family': 'Hezbri', 'given': 'Karima', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of Preventive Medicine, Fattouma Bourguiba University ' 'Hospital , 5000 Monastir , Tunisia'}], 'family': 'Belguith', 'given': 'Asma', 'sequence': 'additional'}, { 'affiliation': [{'name': 'District hospital Teboulba , Tunisia'}], 'family': 'Belkacem', 'given': 'Naouel', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Department of cardiology, Fattouma Bourguiba University Hospital ' ', 5000 Monastir , Tunisia'}], 'family': 'Dridi', 'given': 'Zohra', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Emergency Department, Fattouma Bourguiba University Hospital , ' '5000 Monastir , Tunisia'}, { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}], 'family': 'Boubaker', 'given': 'Hamdi', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}, { 'name': 'Emergency Department, Sahloul University Hospital , 4011 Sousse ' ', Tunisia'}], 'family': 'Boukef', 'given': 'Riadh', 'sequence': 'additional'}, { 'affiliation': [ { 'name': 'Emergency Department, Fattouma Bourguiba University Hospital , ' '5000 Monastir , Tunisia'}, { 'name': 'Research Laboratory LR12SP18 University of Monastir , 5019 ' 'Monastir , Tunisia'}], 'family': 'Nouira', 'given': 'Semir', 'sequence': 'additional'}], 'container-title': 'Clinical Infectious Diseases', 'content-domain': {'crossmark-restriction': False, 'domain': []}, 'created': {'date-parts': [[2022, 10, 3]], 'date-time': '2022-10-03T20:06:47Z', 'timestamp': 1664827607000}, 'deposited': { 'date-parts': [[2022, 11, 3]], 'date-time': '2022-11-03T20:27:59Z', 'timestamp': 1667507279000}, 'indexed': {'date-parts': [[2022, 11, 3]], 'date-time': '2022-11-03T20:40:28Z', 'timestamp': 1667508028429}, 'is-referenced-by-count': 0, 'issued': {'date-parts': [[2022, 11, 4]]}, 'language': 'en', 'license': [ { 'URL': 'https://academic.oup.com/pages/standard-publication-reuse-rights', 'content-version': 'am', 'delay-in-days': 0, 'start': { 'date-parts': [[2022, 11, 4]], 'date-time': '2022-11-04T00:00:00Z', 'timestamp': 1667520000000}}], 'link': [ { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac807/46782455/ciac807.pdf', 'content-type': 'application/pdf', 'content-version': 'am', 'intended-application': 'syndication'}, { 'URL': 'https://academic.oup.com/cid/advance-article-pdf/doi/10.1093/cid/ciac807/46782455/ciac807.pdf', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'member': '286', 'original-title': [], 'prefix': '10.1093', 'published': {'date-parts': [[2022, 11, 4]]}, 'published-online': {'date-parts': [[2022, 11, 4]]}, 'publisher': 'Oxford University Press (OUP)', 'reference-count': 0, 'references-count': 0, 'relation': {}, 'resource': { 'primary': { 'URL': 'https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac807/6795268'}}, 'score': 1, 'short-title': [], 'source': 'Crossref', 'subject': ['Infectious Diseases', 'Microbiology (medical)'], 'subtitle': [], 'title': 'Twice daily oral zinc in the treatment of patients with Coronavirus Disease-19 <i>A randomized ' 'double-blind controlled trial</i>', 'type': 'journal-article'}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit